CORONA, Calif., June 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today the issuance by the United States Patent and Trademark Office of patent number 6,743,441, entitled "Compositions and Methods for Minimizing Adverse Drug Experiences Associated with Oxybutynin Therapy." This patent covers methods of treatment and certain articles of manufacture for treating overactive bladder. Oral oxybutynin therapy is often associated with anticholinergic side effects, such as dry mouth and constipation. By controlling blood levels of oxybutynin and its metabolites through transdermal administration, the incidence and/or severity of these adverse drug experiences can be significantly reduced.
To date, Watson has four patents issued covering various aspects of OXYTROL(R), with this latest patent expiring in 2020. Additional patent applications are pending with the U.S. Patent and Trademark Office and various foreign jurisdictions.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
For press releases and other company information, visit Watson Pharmaceutical's Web site at http://www.watsonpharm.com/.
Forward-Looking Statement
Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing, market acceptance of and demand for Watson's products, patents and other intellectual property rights held by competitors and other third parties, Watson's ability to successfully enforce its patents and other intellectual property rights, and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2003 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2004.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comWatson Pharmaceuticals, Inc.CONTACT: Patty Eisenhaur of Watson Pharmaceuticals, Inc.,+1-909-493-5611
Web site: http://www.watsonpharm.com/
